Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)
89 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
89
Total Reports
87
Deaths Reported
9780.0%
Death Rate
Active Ingredients
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)
Administration Routes
Unknown
Species Affected
Fish 88
Unknown 1
Most Affected Breeds
Atlantic Salmon (Salmo salar) 88
Unknown 1
Most Reported Reactions
Death 63
IGA Animal mortality greater than expected 35
Fish body deformity 28
Moribund 24
IGA Animal morbidity greater than expected 17
Death by euthanasia 14
Partial lack of efficacy 2
Product Defect, General 2
Genotypic test failure (IGA) 2
Unrelated death 1
Fungal skin infection NOS 1
Containment system or component failure (IGA) 1
Outcome Breakdown
Died
63 (59.4%)
Euthanized
39 (36.8%)
Ongoing
4 (3.8%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.